Liva Healthcare acquires Momenta, and secures funding from new and existing investors to drive growth

• Purchase of UK-based Discover Momenta and Momenta Newcastle (‘Momenta’) for undisclosed amount
• Acquisition will significantly increase Liva’s reach and reflects strong synergies, as both companies provide evidence-based programmes for patients with lifestyle-related chronic conditions
• Funding secured from Nupo / IBL Group, a new strategic investor, and existing investors

Copenhagen, Denmark, and London, UK, 5 February 2025 - Liva Healthcare (“Liva” or “the Company”), a digital health technology platform with human-led therapeutic intervention programmes that deliver best-in-class outcomes for lifestyle-related chronic diseases, today announces that it has acquired UK-based Discover Momenta, including subsidiary Momenta Newcastle, for an undisclosed sum. The acquisition of Momenta is part of Liva’s growth strategy as it emerges as a major international provider of evidence-based therapeutic lifestyle interventions.

Momenta provides and licenses digital, virtual, and in-person healthy lifestyle programmes to National Health Service (NHS) organisations, local authorities and other third parties across the UK.

The purchase of Momenta comes as Liva has secured additional funding to accelerate its growth plans. The fundraising was led by a new investor, IBL Group, a Danish family-owned investment company, through its portfolio company Nupo, with participation from existing investors MIG, Santos, Maj Invest and other private investors.

Shahram Sharif, CEO of Liva Healthcare, said: “Today’s news marks a step-change in Liva’s ambitions, as we embark on a revamped strategic growth plan to help more people prevent, manage and reverse their chronic conditions. Momenta is a highly regarded supplier of evidence-based healthy lifestyle programmes, and this acquisition cements Liva’s position as one of the largest providers of such services to the NHS in England. The purchase has been enabled by the investment from IBL Group / Nupo, who we are delighted to welcome as a new investor.

“Liva has been growing rapidly over the last few years and has now enabled over 80,000 patients to better manage or even reverse their chronic conditions. These developments put the Company on the front foot as we seek to become the go-to provider of these evidence-based disease management programmes in Europe and beyond.”

Harry MacMillan, CEO of Momenta, who joins the leadership team of Liva Healthcare, said: “Momenta and Liva share the same vision, and I am delighted we are joining forces. Our combined track records in programme and platform development and digital, virtual and in-person delivery are highly complementary. Liva’s digital platform will enable many more people across the UK and beyond to benefit from Momenta’s expert-developed chronic disease management programmes. This scalability is essential to stem the rising tide of chronic conditions such as obesity, Type 2 diabetes, and cardiovascular disease in a meaningful and cost-effective way.”

Peter Wedelheim, CEO of Nupo, which is backed by IBL Group, said: “The combination of advanced digital technology, including AI, with personalised coaching means that Liva is perfectly positioned to help the growing numbers of people around the world who are suffering from these lifestyle-related chronic conditions. We are excited to be working with them to bring the benefits of this approach to the many patients who can benefit.”